6-Methoxy-5-(4-methyl-1H-imidazol-1-YL)pyridin-2-amine → N-(6-Methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine

HRID 622노트

반응식

HRID 622 반응식
COc1nc(N)ccc1-n1cnc(C)c1.Cc1cnc(C2CN(C)Cc3ccc(Cl)nc3O2)s1>CC(=O)O.CC(=O)O.COCCOC.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(-c2ccccc2P(C2CCCCC2)C2CCCCC2)cc1>COc1nc(Nc2ccc3c(n2)OC(c2ncc(C)s2)CN(C)C3)ccc1-n1cnc(C)c1

참가 물질

7

반응물 2

HCID 534029676-Methoxy-5-(4-methyl-1H-imidazol-1-YL)pyridin-2-amineHCID 57512921HCID 57512921, 화합물

생성물 1

HCID 57512844N-(6-Methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine수율 73.84%

시약·촉매·용매 4

HCID 10796Cesium carbonate시약HCID 27342162-(Dicyclohexylphosphino)biphenyl촉매HCID 4144353Palladium (II) acetate촉매HCID 80711,2-Dimethoxyethane용매

반응 조건

온도
100 °C

실험 절차

8-chloro-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (140 mg, 0.47 mmol), 6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-amine (106 mg, 0.52 mmol), 2-(DICYCLOHEXYLPHOSPHINO)BIPHENYL (16.59 mg, 0.05 mmol), PALLADIUM(II) ACETATE (10.63 mg, 0.05 mmol) and Cs2CO3 (308 mg, 0.95 mmol) were weighed into a microwave vial, the vial was capped and DME (4 mL) was added. The vial was flushed with argon and heated to 100°C in a microwave reactor for 1 h. The reaction mixture was diluted with dichloromethane and filtered and the solvents were evaporated. The residue was purified by column chromatography on Silica using gradient elution with methanol in dichloromethane (0-6 %) to give N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine (162 mg, 73.8 %).

출처 및 근거

ORD 기록
ord-771383a2857c4cf6924928bdcc9bb648
출처 데이터셋
750 AstraZeneca ELN dataset
원본 링크
출처 보기

반응 노트

불러오는 중…